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Cardiac tumours are relatively rare and are difficult to diagnose merely with imaging techniques. We demonstrated
an unusual case of left atrial myxoma, displaying the successful detection by positron emission tomography using
2-deoxy-2-[18 F] fluoro-D-glucose (18 F-FDG PET), correlated closely to more intense and enhanced immunoreactivity
with glucose transporter-1 (GLUT-1) in a substantial number of cardiac myxoma cells. Further prospective studies
are needed to validate the significance of 18 F-FDG PET findings for cardiac myxoma and the association with
immunohistochemical GLUT-1 expression in its tumour cells, after collecting and investigating a larger number of
surgical cases examined with both of them.
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The imaging technique of positron emission tomography
with 2-deoxy-2-[18 F] fluoro-D-glucose (18 F-FDG PET)
is based on the early observations by Warburg, that
neoplastic (especially, malignant) cells accumulate more
glucose than non-neoplastic cells do, as a result of high
rate of glycolytic catabolism rather than citric acid cycle
catabolism [1]. 18 F-FDG PET has thus been increasingly
performed in the diagnosis, pre-operative cancer staging,
or follow-up post-treatment examination of many types
of malignancy, whereas few studies have been reported
regarding the utility of 18 F-FDG PET in intracardiac
tumours [2-4]. Herein we reported an unusual case of left
atrial myxoma, showing the successful detection by its
technique, correlated closely to greater immunoreactivity
with glucose transporter-1 (GLUT-1) in a larger number
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unless otherwise stated.The patient presented here, a 61-year-old female with
an unremarkable previous medical history, had no specific
clinical symptoms for long periods before the diagnosis.
Laboratory data, including blood cell count, chemistry and
tumour markers, or electrocardiogram (ECG) were also
within normal limits. A detailed medical health examin-
ation incidentally detected an intracardiac tumour lesion
by a combined 18 F-FDG PET/CT scan. Coronal maximum
intensity projection (Figure 1A) and axial (Figure 1B)
images in coregistered 18 F-FDG PET/CT showed a
large and mildly to moderately hypermetabolic area in the
left atrium (maximal standardized uptake value (SUV):
3.0), which corresponded to a hypodensisty mass lesion on
chest CT (Figure 1C), measuring 46 × 32 mm in diameter.
Subsequent transthoracic echocardiography (Figure 1D)
demonstrated a pedunculated mass originating from the
interatrial septum, highly suggestive of left atrial myxoma.
Moreover, the neck, chest, and abdomen disclosed no def-
inite evidence of tumour lesions, such as metastatic foci in
the lymph nodes or other organs. Surgeons also consid-
ered to be a benign intracardiac myxoma and performed a
simple excision with repair of the resulting septal defect
by a pericardial patch. On gross examination, a gelatinousl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 The findings of 18 F-FDG PET/CT and echocardiography at surgery of the resected cardiac myxoma. (A–C) Coregistered 18 F-FDG
PET/CT images in coronal (A) and axial (B) plane demonstrated a large and mildly to moderately hypermetabolic area in the left atrium (maximal
SUV: 3.0), which corresponded to a hypodensisty mass lesion on chest CT (C), measuring 46 × 32 mm in diameter. (D) Subsequent transthoracic
echocardiography revealed a pedunculated mass originating from the interatrial septum (arrows).
Figure 2 Microscopic and immunohistochemical examination of the left axial myxoma. (A) Medium power view showed an acellular to
partly cellular proliferation of spindled tumour cells without significant atypia, arranged in variably ring-like structures surrounding small blood
vessels with a lymphoplasmacytic infiltrate, embedded in a prominent Alcian-Blue-positive myxoid matrix (inset) (H&E stains). Bar = 200 μm. (B)
On high-power view, the tumour cells had oval to spindle nuclei, eosinophilic cytoplasm and indistinct cell borders, and inconspicuous nucleoli,
manifesting as so-called ‘myxoma cells’ and ‘lepidic cells’, appearing as short cords or syncytia (H&E stains). Bar = 50 μm. (C) In immunohistochemistry,
the myxoma cells were specifically positive for CD31 (lt.) and CD34 (rt.). Bar = 20 μm. (D) Interestingly, a substantial number of these myxoma cells were
immunoreactive with GLUT-1 in a cytoplasmic and membranous expression pattern. Bar = 50 μm.
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http://www.diagnosticpathology.org/content/9/1/117tumour with a relatively smooth surface was attached to
the fossa ovaris by a narrow stalk, and there were no orga-
nized thrombi on the surface. Its cut surface showed a
well-circumscribed, encapsulated and variegated mass,
measuring approximately 40 × 35 mm in diameter, which
looked hemorrhagic in color and displayed a gelatinous
appearance with gritty calcified areas. Microscopic find-
ings demonstrated an acellular to partly cellular prolifera-
tion of spindled tumour cells without significant atypia,
arranged in variably ring-like structures surrounding small
blood vessels with a lymphoplasmacytic infiltrate, embed-
ded in a prominent Alcian-Blue-positive myxoid matrix
with frequent hemorrhage or hemosiderin pigments,
and focal hyalinized fibrosis, ossification or calcification
(Figure 2A). On high-power view, the tumour cells had
oval to spindle nuclei, eosinophilic cytoplasm and indis-
tinct cell borders, and inconspicuous nucleoli, manifesting
as so-called ‘myxoma cells’ and ‘lepidic cells’, appearing as
short cords or syncytia (Figure 2B). Overall, the main
features were consistent with typical cardiac myxoma. In
immunohistochemistry [5], those myxoma cells were posi-
tive for CD31 (Dako, Glostrup, Denmark, diluted 1:20)
and strongly positive for CD34 (Immuno Tech. Co., Ltd.,
Osaka, Japan, diluted 1:150) (Figure 2C). Interestingly, a
substantial number of them were immunoreactive with
GLUT-1 (Dako, diluted 1:600) in a cytoplasmic and mem-
branous expression pattern (Figure 2D). In contrast, they
were completely negative for cytokeratin (AE1/AE3; Dako,
diluted 1:500), CD68 (KP-1; Dako, diluted 1:100),
Podoplanin (D2-40; Nichirei Bioscience Co., Tokyo, Japan;
diluted 1:1), α-SMA (Dako, diluted 1:500), desmin (Dako,
diluted 1:300), or S-100 protein (Dako, diluted 1:900). The
MIB-1 labeling index (Ki67; Dako, diluted 1:50) was noted
in less than 1 to 3% in the myxoma cells. Based on all
these features, we finally made a diagnosis of left atrial
myxoma. To date, approximately 1 year routine follow-up
after the surgery is established, and the patient remains
well and no recurrence has been identified.
Indeed, myxomas, as many as 60% of relatively rare
cardiac tumours, could be considered to be common
diseases, compared with some recently published papers
of very unusual tumour cell types or features in the
heart [2,6]. Despite that, merely three case reports of
atrial myxoma have demonstrated its appearance and
utility in 18 F-FDG PET, revealing a moderately elevated
glucose metabolism, very similar to our case, and likely
assuming an established position in the routine clinical
evaluation of cardiac tumours [2-4]. Furthermore, we
describe the present unusual case, since it is conceivable
that the current short report of cardiac myxoma located
on the left atrium is clinicopathologically remarkable for
another reason at least. A higher 18 F-FDG uptake rate in
the present case could have a close correlation with a more
specific and greater immunohistochemical expression ofGLUT-1 in the myxoma cells, corresponding to the malig-
nant cells in intraductal papillary mucinous neoplasms of
the pancreas, as previously reported [7]. Enhanced expres-
sion of GLUT-1 has actually been recognized in various
cancer tissues examined, since one of the pivotal functions
of ubiquitous GLUT-1 is known to particularly increase
the glucose supply to dividing and growing cells in part,
among a family of GLUT transporters [8,9], possibly unlike
these benign myxoma cells with relatively low MIB-1
index. However, the potential biological roles of accelerated
glucose utilization in neoplastic cells still remain to be
elucidated in detail. Nevertheless, it would be intriguing to
assess the significance of 18 F-FDG PET findings for cardiac
myxoma and the association with immunohistochemical
GLUT-1 expression in the myxoma cells on future larger
studies. The present short case report could interest the
scientific community, taken together with potentially new
and specific clinicopathological findings.Consent
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